{"id":"genhevac-b-pasteur","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or swelling"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1160385","moleculeType":"Small molecule","molecularWeight":"182.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains recombinant hepatitis B surface antigen (HBsAg) produced in yeast cells, which triggers both humoral and cellular immune responses. This leads to the production of protective antibodies (anti-HBs) and memory B cells that provide long-term immunity against hepatitis B virus infection.","oneSentence":"GenHevac B Pasteur is a recombinant hepatitis B vaccine that stimulates the immune system to produce antibodies against hepatitis B surface antigen.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:54.641Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis B infection in adults and children"}]},"trialDetails":[{"nctId":"NCT01698866","phase":"PHASE4","title":"Low Grade Lymphoma","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","startDate":"2012-07","conditions":"Indolent Lymphoproliferative Disorders","enrollment":40},{"nctId":"NCT00670839","phase":"PHASE3","title":"Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2008-05","conditions":"Hepatitis B, HIV Infection","enrollment":178},{"nctId":"NCT00480792","phase":"PHASE3","title":"Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2007-06","conditions":"HIV Infections","enrollment":437}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sanofi Pasteur MSD"],"phase":"phase_3","status":"active","brandName":"GenHevac B Pasteur","genericName":"GenHevac B Pasteur","companyName":"ANRS, Emerging Infectious Diseases","companyId":"anrs-emerging-infectious-diseases","modality":"Biologic","firstApprovalDate":"","aiSummary":"GenHevac B Pasteur is a recombinant hepatitis B vaccine that stimulates the immune system to produce antibodies against hepatitis B surface antigen. Used for Prevention of hepatitis B infection in adults and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}